Apr 10, 2025 7:42 am EDT OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Apr 09, 2025 7:40 am EDT OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Apr 07, 2025 6:00 am EDT OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Mar 31, 2025 4:30 pm EDT OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
Mar 31, 2025 7:40 am EDT OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Mar 25, 2025 7:40 am EDT OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Mar 21, 2025 7:40 am EDT OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
Mar 13, 2025 7:40 am EDT OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Mar 11, 2025 7:40 am EDT OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma